






# Develop Anti-Cancer Therapeutics for HER2 low Gastric Cancers by Combining Targeting Peptide and NanoCarrier

**KMD Bio Ltd**

Disease area	Cancer
Product Type	Drug Delivery System : Antibody Conjugated NanoParticles (ACNP)
Indication	Stomach Cancer, Breast Cancer, Hepatobiliary Cancer
Target	HER2 overexpressed solid cancers, HER2 low (mild/moderate expressed) solid cancers
Mechanism of Action	Combining Active CancerTargeting (Receptor Mediated Endocytosis) and Passive Cancer Targeting (Enhanced Permeability and Retention)
Competitiveness	1. Highly effective cancer targeting 2. Deliver exponential number of payload to targeted cancer. 3. Utilize non-favorable payloads either being insoluble or highly toxic to normal cell 4. Expand pipelines by switching targeting peptides and/or payloads 5. Driving synergy by double targeting and dual payloads (loading two different targeting agents and/or payloads)
Development Stage	Candidate
Route of Administration	IV
Key Data	<div><div><div>Targeted NanoCarrier</div></div><div><div>ACNP (Antibody Conjugated NanoParticles)</div></div><div><div>Cancer Targeting &amp; Macrophage Escaping</div></div><div><div>Fluorescence images SK-BR3 tumor xenograft</div></div><div><div>Tumor growth inhibition in HER2(SK-BR3) Xenograft</div></div></div>
IP	PX230083PCT, 16/767,864 (US), 18884380.9 (UK), 10-2112269(KR)